VANCOUVER, British Columbia, June 04, 2025 (GLOBE NEWSWIRE) -- Eldorado Gold Corporation ("Eldorado" or "the Company") is pleased to announce that all director nominees, as listed in the Management Proxy Circular dated April 15, 2025, were elected as directors of Eldorado at the Company's Annual and Special Meeting of Shareholders (the "Meeting") held on June 3, 2025. "On behalf of the Board, we would like to thank our shareholders for their continued support. With our transformative Skouries copper-gold pr ...

Check-Cap Ltd. Issues Strong Condemnation of MediPharm Labs Chairman Chris Taves for Fabricated Defamatory Statements Press Releases Taves Times his Attack to Commence 23 Minutes before the Start of Shabbat to Delay the Company from Responding ISFIYA, ISRAEL, June 04, 2025 (GLOBE NEWSWIRE) -- Check-Cap Ltd. (NASDAQ: CHEK) ("Check- Cap" or the "Company"), a clinical-stage medical diagnostics company incorporated in Israel, today publicly condemned MediPharm Labs Corp. (LABS) ("MediPharm Labs") and its Chairm ...

Cohort 3 demonstrates earlier and deeper responses compared to cohorts 1-2 All three cohorts show separation from placebo with statistically significant difference from placebo at day 28 Cohort 3 demonstrates clinically meaningful reduction in itch as early as day 8 Enrollment initiated in extension cohort study exploring the same cohort 3 dose (200 mg BID) for a longer 8- week treatment period SOUTH SAN FRANCISCO, Calif., June 04, 2025 (GLOBE NEWSWIRE) -- Corvus Pharmaceuticals, Inc. (NASDAQ: CRVS), a clin ...

WALTHAM, Mass., June 04, 2025 (GLOBE NEWSWIRE) -- Apellis Pharmaceuticals, Inc. (Nasdaq: APLS) today announced that the company will present at the Goldman Sachs 46th Annual Global Healthcare Conference on Wednesday, June 11, 2025 at 10:40 a.m. ET. The live conference webcast will be posted on the “Events and Presentations” page of the “Investors and Media” section of the company’s website. A replay of the webcast will be available for approximately 90 days following the event. About ApellisApellis Pharmace ...

WATERTOWN, Mass., June 04, 2025 (GLOBE NEWSWIRE) -- Vigil Neuroscience, Inc. (Nasdaq: VIGL), a clinical-stage biotechnology company committed to harnessing the power of microglia for the treatment of neurodegenerative diseases, today announced an update on the Phase 2 IGNITE open-label clinical trial evaluating iluzanebart, a monoclonal antibody TREM2 agonist, for the potential treatment of adult-onset leukoencephalopathy with axonal spheroids and pigmented glia (ALSP). Iluzanebart demonstrated a favorable ...

Taavi Gröön AS Tallinna Vesi CFO (+372) 62 62 200 taavi.groon@tvesi.ee Proceeding from the above, the ex-date is 09 June 2025. From that date the new owner of the shares is not entitled to dividends for the year 2024. AS Tallinna Vesi will pay dividend 0.53 euro per share. Dividends are paid out to shareholders on 17 June 2025. AS Tallinna Vesi (trading code TVE1T, ISIN code EE3100026436) will close the list of shareholders for dividend payment on 10 June 2025 at the end of the working day of the settlement ...

The Panel further reminded the Company that it is also required to regain compliance with the equity requirement in Listing Rule 5550(b)(1) (the "Equity Rule") by June 30, 2025 under the extension previously granted by the Panel. Accordingly, the Nasdaq Listing Qualifications hearing process will remain open until the Company has demonstrated compliance with all of The Nasdaq Stock Market's continued listing requirements. About Helius Medical Technologies, Inc. Helius Medical Technologies is a leading neuro ...

Sharps has initiated shipment of its first commercial order of Sologard under a previously announced $50 million supply agreement with a U.S.-based leader in IV flushing solutions. The delivery includes customized 10mL SoloGard smart safety syringes manufactured at the Company's upgraded facility in Hungary. SoloGard is a specialized, FDA- and WHO-approved smart safety syringe featuring ultra-low waste design, standard luer lock compatibility, and re-use prevention technology. This inaugural $400,000 purcha ...

Core Insights - Brookfield Asset Management announced an investment of up to SEK 95 billion ($10 billion) to develop AI infrastructure in Sweden, marking one of its largest AI investments in Europe and strengthening its partnership with the Swedish government and local entities [1][2][3] Investment Details - The investment will focus on a new AI center in Strängnäs, Sweden, which will support the national AI strategy and significantly increase the data center's capacity from 300MW to 750MW by acquiring approximately 350,000 sqm of additional land [2][3] - The new facility is expected to create over 1,000 permanent jobs and an additional 2,000 jobs during the 10-15 year construction period, making it the first of its kind in Sweden and one of the first in Europe [2][3] Strategic Importance - The investment is part of Brookfield's broader strategy to enhance AI infrastructure, which includes not only data centers but also data transfer, chip storage, and energy generation, aimed at boosting sovereign compute capabilities for both public and private sectors in Europe [3] - Brookfield has invested over €100 billion globally in the AI value chain, including a recent €20 billion infrastructure investment program in France, which features a €10 billion investment in the first AI factory in the country [3] Historical Context - Brookfield has been actively investing in Sweden since 2018, with a diverse portfolio that includes telecom towers, renewable power, social infrastructure, and logistics assets [4]

Core Insights - Revive Therapeutics Ltd. is advancing its next-generation lyophilized formulation of Bucillamine, developed in collaboration with the University of Waterloo, to address significant unmet medical needs and create shareholder value [1][6] Strategic Development - The company is targeting public health emergencies, including pandemic influenza and emerging infectious diseases, while pursuing FDA incentives such as Emergency Use Authorization and Orphan Drug Designation to facilitate rapid market entry [2][6] Product Potential - Bucillamine has FDA Orphan Drug Designation for ischemia-reperfusion injury following solid organ transplantation, awarded in 2022, indicating its promise and potential for accelerated development [3] - Research suggests Bucillamine may enhance solid tumor treatments in cancer, with interest from a prominent clinical researcher to investigate its anti-tumor effects in patients with advanced solid tumors [3] Partnerships and Research - Revive is collaborating with Defence R&D Canada on a study evaluating Bucillamine for nerve agent exposure, with positive results expected by June 2025, potentially leading to human clinical trials and subsequent FDA and Health Canada approvals [4] - The potential applications of Bucillamine also include traumatic brain injury and viral infections, expanding its market potential [4] Ongoing Developments - The company is in the process of settling a previously announced arbitration award with LTS Lohmann Therapie-System AG [5]